Authors

• Mario Udovičić — Dubrava University Hospital, Zagreb, Croatia — ORCID: 0000-0001-9912-2179
• Nika Barbara Pravica — Dubrava University Hospital, Zagreb, Croatia — ORCID: 0000-0001-5478-2392
• Mihovil Santini — Dubrava University Hospital, Zagreb, Croatia — ORCID: 0000-0002-1428-4484
• Danijela Grizelj — Dubrava University Hospital, Zagreb, Croatia — ORCID: 0000-0002-8298-7974
• Vanja Ivanović Mihajlović — Dubrava University Hospital, Zagreb, Croatia — ORCID: 0000-0001-6931-5404
• Hrvoje Falak — Dubrava University Hospital, Zagreb, Croatia — ORCID: 0000-0002-6502-683X
• Igor Rudež — Dubrava University Hospital, Zagreb, Croatia — ORCID: 0000-0002-7735-6721
• Davor Barić — Dubrava University Hospital, Zagreb, Croatia — ORCID: 0000-0001-5955-0275
• Daniel Unić — Dubrava University Hospital, Zagreb, Croatia — ORCID: 0000-0003-2740-4067
• Robert Blažeković — Dubrava University Hospital, Zagreb, Croatia — ORCID: 0000-0001-7125-361X
• Josip Varvodić — Dubrava University Hospital, Zagreb, Croatia — ORCID: 0000-0001-6602-699X
• Dubravka Šušnjar — Dubrava University Hospital, Zagreb, Croatia — ORCID: 0000-0002-9644-9739
• Šime Manola — Dubrava University Hospital, Zagreb, Croatia — ORCID: 0000-0001-6444-2674

Keywords

advanced heart failure, heart transplantation, prognosis

DOI

Full Text

**Introduction:** Heart transplantation (HTx) remains the gold standard and treatment of choice for advanced heart failure refractory to other methods (1). In this study we investigated the outcomes of patients after HTx undergoing follow up at the Department of Cardiology, Dubrava University Hospital and their dependence upon the recipient characteristics at the time of HTx. **Patients and Methods:** We retrospectively examined the outcomes from 120 HTx between 1995 and November 2022, the recipient characteristics, and the impact of their comorbidities on survival. **Results:** The mean recipient age was 53.6 years at the time of HTx, and 80.8% were male. Dilated cardiomyopathy was present in 51%, ischemic in 41% and 8% were other causes. Survival was studied using Kaplan-Meier curves. Early in-hospital mortality was 10.0%. The survival rates at 1, 5, and 10 years were 83.9%, 74.5% and 56.3% respectively, and the mean survival was 132.9 months (95% CI, 110.5-155.3). Among the characteristics of the donors, none was found to separately have an impact on survival. However, the Charlson Comorbidity Index (CCI) ≥ 5 at the time of HTx was associated with a reduced survival, with a mean survival time of 91.0 months (95% CI, 67.0-115.0) compared to the group with CCI <5, whose mean survival of 157.4 months (95% CI, 129.6-185.2) was significantly better (p=0.004). **Conclusion:** Heart transplantation remains an excellent treatment option for selected patients with advanced heart failure, but our data implies that the high overall recipient comorbidity burden negatively impacts the posttransplant survival.

Literature

1. McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021 September 21;42(36):3599–726. https://doi.org/10.1093/eurheartj/ehab368